The five negative symptoms of schizophrenia are affective flattening (blunted affect), alogia, anhedonia, asociality, and avolition. Often called the “five A’s,” these symptoms represent things that are reduced or absent: emotional expression, speech, pleasure, social drive, and motivation. Unlike the more recognizable “positive” symptoms of schizophrenia, such as hallucinations and delusions, negative symptoms involve a loss of normal functioning rather than the addition of unusual experiences.
Affective Flattening (Blunted Affect)
Affective flattening refers to a decreased expression of emotion. A person with this symptom may speak in a monotone voice, show little facial expression, and make fewer gestures during conversation. Their emotional responses appear muted or absent, even when discussing something that would normally provoke strong feelings. It’s important to understand that this is about outward expression. The person may still feel emotions internally but lack the ability to display them in ways others can read. This disconnect often makes social interactions feel strained or confusing for both sides.
Alogia
Alogia is a reduction in the quantity of words spoken. Conversations become noticeably brief. Responses may be limited to one or two words, and the person rarely volunteers information or elaborates on answers. This isn’t shyness or a preference for quiet. The person genuinely struggles to produce speech, and when they do speak, their responses can feel empty or disconnected from the flow of conversation. Alogia is one of the symptoms clinicians look for when assessing negative symptoms on standardized scales, where it falls under “lack of spontaneity and flow of conversation.”
Anhedonia
Anhedonia is a reduced ability to experience pleasure, either during an activity or in anticipation of one. This is one of the most misunderstood negative symptoms because of what researchers call the “anhedonia paradox.” People with schizophrenia can often enjoy a pleasant moment while it’s happening, but they struggle to carry that feeling forward. They don’t anticipate future enjoyment the way most people do. So while someone might laugh at a joke or enjoy a meal in the moment, they won’t look forward to the next joke or the next meal. This breaks the motivational link between past enjoyment and future action, making it hard to plan activities or pursue hobbies. The result looks like apathy from the outside, but the internal experience is more like a broken bridge between “that was nice” and “I want to do that again.”
Asociality
Asociality is a reduced interest in social relationships and a decline in social initiative. A person with asociality may stop reaching out to friends, avoid family gatherings, or sit silently in group settings without engaging. This differs from social anxiety, where a person wants connection but fears it. In asociality, the desire for social contact itself is diminished. The person doesn’t feel lonely in the way you might expect. They simply experience less pull toward being around other people. Over time, this can lead to significant social isolation, which compounds other symptoms and makes recovery harder.
Avolition
Avolition is reduced motivation to initiate and sustain goal-directed activity. It shows up as difficulty starting tasks, maintaining hygiene, keeping a job, or following through on plans. A person with avolition may sit for hours without doing anything, not because they’re tired or depressed, but because the internal drive to act is diminished. This is one of the most functionally damaging negative symptoms. Research on employment outcomes in people with schizophrenia has found that these “experiential” or motivational symptoms are closely linked to whether someone obtains a job, how many hours they work, and how much they earn.
Two Clusters: Expressive vs. Experiential
Clinicians increasingly group the five symptoms into two clusters. The expressive cluster includes affective flattening and alogia, both of which involve reduced outward expression. The experiential cluster includes anhedonia, asociality, and avolition, which involve reduced internal motivation and engagement. This distinction matters because the two clusters can respond differently to treatment and have different effects on daily life. The experiential symptoms tend to be more damaging to long-term functioning, particularly employment and independent living, while the expressive symptoms more visibly affect social interactions and relationships.
Primary vs. Secondary Negative Symptoms
Not all negative symptoms come directly from schizophrenia itself. Primary negative symptoms are considered part of the disease’s core biology. Secondary negative symptoms look identical but stem from other causes: side effects of antipsychotic medication (which can cause emotional blunting and sluggishness), depression, social deprivation, substance use, or even the withdrawal that comes from dealing with active hallucinations or paranoia.
The distinction is critical because treating a secondary negative symptom requires addressing its actual cause, whether that means adjusting a medication, treating depression, or reducing social isolation. Misidentifying secondary symptoms as primary ones can lead clinicians to assume the disease is worsening when the real problem is a treatable side effect. For a negative symptom to be classified as truly persistent, it generally needs to be present for at least six months during a period of clinical stability, without significant depression or medication-related movement side effects.
What Causes Negative Symptoms in the Brain
Schizophrenia involves a complex imbalance of dopamine signaling across different brain regions. Positive symptoms like hallucinations are linked to excess dopamine activity in deeper brain structures. Negative symptoms, by contrast, appear to involve too little dopamine activity in the prefrontal cortex, the brain region responsible for motivation, planning, and emotional regulation. Reduced dopamine signaling in the brain’s reward center (the nucleus accumbens) also plays a role, particularly in avolition. Brain imaging studies have shown that people with severe avolition have a diminished response in reward-processing areas when anticipating something pleasant.
Another layer involves the brain’s glutamate system, which interacts with dopamine signaling. Dysfunction in glutamate receptors, particularly in the prefrontal cortex, is considered one of the earliest developmental abnormalities associated with schizophrenia and may contribute to both negative symptoms and cognitive difficulties.
How Negative Symptoms Are Treated
Negative symptoms are widely considered the hardest part of schizophrenia to treat. Standard antipsychotic medications are effective at reducing hallucinations and delusions but have limited impact on negative symptoms. A large meta-analysis of dose-response data found that most antipsychotics reach their near-maximum effect on negative symptoms at lower doses than needed for positive symptoms, but even that maximum effect is modest. There is no medication currently approved specifically for negative symptoms.
Psychosocial interventions have shown more consistent results. Social skills training, in which people practice conversational and interpersonal skills in structured settings, produces medium-sized improvements in negative symptoms and functioning. A meta-analysis of 27 clinical trials found that these effects held up when compared to both standard care and other active treatments, and the benefits lasted up to a year after the training ended. The combination of skills training with supported employment or structured daily activities tends to address the functional consequences of avolition and asociality more directly than medication alone.
Several experimental drug approaches are being tested that target the glutamate system rather than dopamine. One approach involves increasing the availability of a brain chemical called glycine, which helps activate glutamate receptors. Another strategy uses compounds that reduce levels of a substance called kynurenic acid, which normally dampens glutamate signaling. Early-phase trials of these approaches have shown some promising signals in brain imaging and cognitive measures, but none have yet demonstrated clear clinical benefits in large trials. A major Phase III trial program for one leading candidate, iclepertin, failed to meet its primary goals in early 2025.